All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Selumetinib Nets EU Approval for Adult NF1-Associated Plexiform Neurofibromas

October 28th 2025

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Belzutifan-Based Combinations Meet DFS, PFS End Points in Renal Cell Carcinoma

October 28th 2025

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma

October 28th 2025

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer

October 28th 2025

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025

October 28th 2025

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

FDA Awards Fast Track Designation to MT-125 for Glioblastoma

October 28th 2025

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

ELI-002 7P Shows Potential to Address Unmet Need in Pancreatic Ductal Adenocarcinoma

October 27th 2025

Specific HLA types were not found to be associated with robust mKRAS-specific T-cell responses after treatment with ELI-002 7P in patients with PDAC.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma

October 27th 2025

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

October 27th 2025

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

BiTE-Based Immunotherapy Strategy Could Point the Way to a Breakthrough for Ovarian Cancer Patients

October 27th 2025

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.

Neladalkib Showcases Early Activity in ALK+ Solid Tumors

October 27th 2025

Neladalkib showed durable responses and good tolerability in ALK-positive solid tumors, including TKI-pretreated patients, in early ALKOVE-1 results.

ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

October 27th 2025

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Gedatolisib-Based Regimens May Advance PIK3CA Wild-Type Metastatic Breast Cancer Care

October 27th 2025

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

Five Under 5: Top Oncology Videos for the Week of 10/19

October 26th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma

October 26th 2025

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC

October 25th 2025

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC

October 24th 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia

October 24th 2025

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Toripalimab Becomes First Approved Immunotherapy for Recurrent Unresectable/Metastatic NPC in Canada

October 24th 2025

Toripalimab has been approved by Health Canada both as monotherapy and in combination with cisplatin and gemcitabine for recurrent or metastatic NPC.